A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab.
about
Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficitsBone and TNF in rheumatoid arthritis: clinical implicationsEffects of anti-tumor necrosis factor α agents on boneBiologic therapies and bone loss in rheumatoid arthritis.Bone remodelling markers in rheumatoid arthritis.Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologicsEffects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis.Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseasesBone effects of biologic drugs in rheumatoid arthritis.Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER studyPrevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy.Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate.Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.Can bone loss in rheumatoid arthritis be prevented?Classical and Paradoxical Effects of TNF-α on Bone Homeostasis.High-resolution imaging of bone and joint architecture in rheumatoid arthritis.Management of osteoporosis in rheumatoid arthritis patients.The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease.Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.Differential Effects of IL-17A and TNF-α on Osteoblastic Differentiation of Isolated Synoviocytes and on Bone Explants from Arthritis Patients.Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study.Tumour necrosis factor blockade and the risk of osteoporosis: back to the future.Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.Changes in body composition after 2 years with rheumatoid arthritis.Bone mineral density in systemic lupus erythematosus women one year after rituximab therapy.Paradoxical elevation of serum TRACP5b levels despite increase in lumbar spine bone mineral density during anti-TNFα therapy in patients with inflammatory rheumatic disease: a 2-year prospective assessment of bone mass, bone metabolism, and the trabBiologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs.Early Subchondral Bone Loss at Arthritis Onset Predicted Late Arthritis Severity in a Rat Arthritis Model.Short-term daily teriparatide in patients with rheumatoid arthritis.Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study
P2860
Q24653333-08902B8F-B8E9-44B3-8780-F128BA6C3E96Q26777895-7A44A3A5-0EE2-4FAC-9F18-5AFD58385F3CQ26851274-4957101B-D1E1-42BF-960C-CF776F184CE2Q30243911-3865E03C-9D1A-4D01-AE03-76ECD2979E02Q33563068-BFD58EE7-FA8B-4708-B8C9-38D170BB3D5DQ34155014-4A3AB979-766D-49BC-B215-6A967DCCB8E4Q35792875-02DB4340-9C27-47E9-9E1E-1E8D594153EDQ36245404-B0D2EF89-ED11-4A0C-82EE-D3F373701831Q36781280-8EFBC79F-F539-4D76-8CB8-3B82E22808F0Q36995387-5F7B31DB-FECD-4B4F-8684-558B37293B40Q37051820-12CA8022-67AA-48CF-8AA8-7F6EC24F9B37Q37210194-849636F9-C558-4FD8-821A-F862BCB1DCB2Q37307876-B063A3CC-4FD9-4143-BB83-7648308BF966Q37690607-F95B234C-32DF-45A1-8A76-539011FE0142Q37801555-73B46EA6-AA6A-4802-89F2-7374C26C6B90Q38041419-90182595-2F31-4165-A682-F35C991671C6Q38115190-FA6B5782-DF83-49DE-A1C2-0C38E752EA62Q38193090-6BB7C00A-1214-4700-989E-87B9B9715FA9Q38268867-FB34FE92-D289-4839-8AFF-F090519863D3Q38334318-DE5D64F1-1741-405A-B074-5E873B604796Q38831693-ED2415E6-1CFF-473D-9EE6-42EBAE8140B0Q39035413-6B0D9FB2-0A39-4DAF-9BEF-9FB8BFD567E3Q39177137-21B456C6-81E5-4718-9DAA-8FAF1E6E5E58Q39327736-71631973-1771-46FC-82B7-F8E59AAF15BAQ40079134-A96ABC40-3384-4B99-BB2C-C7BF3F09A217Q42963612-C123EE53-B0EE-4C7B-9F41-3585E2466EC8Q43785534-C535AB10-352D-4EC7-BFD0-D9CFC0E94007Q44174557-568BBF84-DA32-4A54-AFF3-13BBC31569C4Q44794499-38EC23A2-7D0C-45B3-B2D7-190E1F9CD669Q45832844-E782F1E8-240B-4359-B4F0-E55A2B1B1D73Q46155482-C53FFB62-EC4B-4DE6-9B81-F1EC5583954BQ47110800-579E7A8B-3F3F-4395-9AE3-C56C91DFADBBQ48000637-1B97EA45-0C6B-473E-9691-39E8DCE3FA68Q48694023-D07125AC-F815-4DF9-97BE-25BE0DF5BFB0Q58799794-9111C4F9-8B7E-42DF-B242-83176F3586C1
P2860
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
A 1-year case-control study in ...... d nonresponders to infliximab.
@ast
A 1-year case-control study in ...... d nonresponders to infliximab.
@en
type
label
A 1-year case-control study in ...... d nonresponders to infliximab.
@ast
A 1-year case-control study in ...... d nonresponders to infliximab.
@en
prefLabel
A 1-year case-control study in ...... d nonresponders to infliximab.
@ast
A 1-year case-control study in ...... d nonresponders to infliximab.
@en
P2093
P2860
P356
P1476
A 1-year case-control study in ...... d nonresponders to infliximab.
@en
P2093
Beatrice Pallot-Prades
Christian Alexandre
Hubert Marotte
Laurent Grange
Philippe Gaudin
P2860
P2888
P356
10.1186/AR2219
P577
2007-01-01T00:00:00Z
P5875
P6179
1001701638